This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 | MicrobiomeTrials
← Back to trials NCT06694805
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-12-02Est. Completion: 2026-08-19
Enrollment target: 326 participantsLocations GSK Investigational Site, Birmingham, Alabama, United States GSK Investigational Site, Los Angeles, California, United States GSK Investigational Site, Los Angeles, California, United States GSK Investigational Site, Los Angeles, California, United States GSK Investigational Site, Aurora, Colorado, United States GSK Investigational Site, Denver, Colorado, United States GSK Investigational Site, New Haven, Connecticut, United States GSK Investigational Site, Newark, Delaware, United States GSK Investigational Site, Washington D.C., District of Columbia, United States GSK Investigational Site, Jacksonville, Florida, United States GSK Investigational Site, Miami, Florida, United States GSK Investigational Site, Sarasota, Florida, United States GSK Investigational Site, West Palm Beach, Florida, United States GSK Investigational Site, Atlanta, Georgia, United States GSK Investigational Site, Decatur, Georgia, United States GSK Investigational Site, Macon, Georgia, United States Other microbiome trials you might be interested in HIV-1-infection Metabolic Syndrome
This study is being done to understand how a physical activity walking intervention affects metabolic parameters (i.e., …
Washington D.C., United States Completed Jun 11, 2025
HIV Infections Opioid Use Disorder
This pilot feasibility study represents part 3 of a larger R61 study, where the investigators will follow a cohort about…
Boston, United States Est. completion Dec 2026
GSK Investigational Site, Chicago, Illinois, United States
GSK Investigational Site, Chicago, Illinois, United States
GSK Investigational Site, Chicago, Illinois, United States
GSK Investigational Site, Baltimore, Maryland, United States
GSK Investigational Site, Baltimore, Maryland, United States
GSK Investigational Site, Boston, Massachusetts, United States
GSK Investigational Site, Berkley, Michigan, United States
GSK Investigational Site, Kansas City, Missouri, United States
GSK Investigational Site, St Louis, Missouri, United States
GSK Investigational Site, Newark, New Jersey, United States
GSK Investigational Site, Hawthorne, New York, United States
GSK Investigational Site, New York, New York, United States
GSK Investigational Site, New York, New York, United States
GSK Investigational Site, The Bronx, New York, United States
GSK Investigational Site, The Bronx, New York, United States
GSK Investigational Site, Greensboro, North Carolina, United States
GSK Investigational Site, Cincinnati, Ohio, United States
GSK Investigational Site, Columbus, Ohio, United States
GSK Investigational Site, Philadelphia, Pennsylvania, United States
GSK Investigational Site, Dallas, Texas, United States
GSK Investigational Site, Houston, Texas, United States
GSK Investigational Site, Seattle, Washington, United States
GSK Investigational Site, Milwaukee, Wisconsin, United States
GSK Investigational Site, Buenos Aires, Argentina
GSK Investigational Site, Buenos Aires, Argentina
GSK Investigational Site, Buenos Aires, Argentina
GSK Investigational Site, Capital Federal, Argentina
GSK Investigational Site, Ciudad Autonoma Buenos Aires, Argentina
GSK Investigational Site, Córdoba, Argentina
GSK Investigational Site, Rosario, Argentina
GSK Investigational Site, Antwerp, Belgium
GSK Investigational Site, Montreal, Quebec, Canada
GSK Investigational Site, Montreal, Quebec, Canada
GSK Investigational Site, Cologne, North Rhine-Westphalia, Germany
GSK Investigational Site, Berlin, Germany
GSK Investigational Site, Cologne, Germany
GSK Investigational Site, Düsseldorf, Germany
GSK Investigational Site, Frankfurt, Germany
GSK Investigational Site, Bari, Italy
GSK Investigational Site, Bergamo, Italy
GSK Investigational Site, Milan, Italy
GSK Investigational Site, Milan, Italy
GSK Investigational Site, Roma, Italy
GSK Investigational Site, Porto, Portugal
GSK Investigational Site, Porto, Portugal
GSK Investigational Site, Barcelona, Spain
GSK Investigational Site, Barcelona, Spain
GSK Investigational Site, Barcelona, Spain
GSK Investigational Site, Barcelona, Spain
GSK Investigational Site, Barcelona, Spain
GSK Investigational Site, Bilbao, Spain
GSK Investigational Site, Cadiz, Spain
GSK Investigational Site, Córdoba, Spain
GSK Investigational Site, Madrid, Spain
GSK Investigational Site, Madrid, Spain
GSK Investigational Site, Madrid, Spain
GSK Investigational Site, Madrid, Spain
GSK Investigational Site, Madrid, Spain
GSK Investigational Site, Madrid, Spain
GSK Investigational Site, Madrid, Spain
GSK Investigational Site, Madrid, Spain
GSK Investigational Site, Málaga, Spain
GSK Investigational Site, Málaga, Spain
GSK Investigational Site, Murcia, Spain
GSK Investigational Site, Palma de Mallorca, Spain
GSK Investigational Site, Sabadell Barcelona, Spain
GSK Investigational Site, Seville, Spain
GSK Investigational Site, Vigo Pontevedra, Spain
GSK Investigational Site, Zaragoza, Spain Recruiting
HIV-1-infection Human Immunodeficiency Virus HIV/AIDS HIV Infections
The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with incr…
Aurora, United States Est. completion Mar 31, 2020